Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is a clinical-stage biopharmaceutical company with a promising CD19 and CD22-targeted ARTEMIS T-cell therapy in development, which addresses treatment challenges for patients with blood cancers and solid tumors. The company's recent completion of an $8M financing and advancement of their therapy into Phase II of its ongoing study, along with onboarding their first Phase II patient, demonstrates strong execution and potential for future success. However, future dilution and potential risks related to clinical, financial, commercial, legal, and intellectual property factors must be considered.

Bears say

Estrella Immunopharma is facing several key challenges that could significantly impact their stock performance. Firstly, their Phase I data for EB103 in aggressive B-cell Non-Hodgkin Lymphoma (NHL), while positive, only covers a small patient population and lacks long-term data. Secondly, there is intense competition in the CAR-T therapy market, and Estrella's technology has yet to be proven in larger clinical trials. Lastly, their valuation is heavily dependent on the success of EB103, with a 30% probability of success and a 30% discount rate, making it a high-risk investment.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.